Protein Sciences out of the gate early with approved Flublok vaccine

MERIDEN, Conn. - Protein Sciences announced Wednesday that the Food and Drug Administration has approved the composition of Flublok influenza vaccine for the 2015/16 flu season.  

 

"We are extremely pleased with the early approval of the 2015/16 Flublok formulation," said Manon Cox, president and CEO of Protein Sciences. "We expect Flublok to be available in Target pharmacies and other retail chains before most other vaccines this year. Flublok is approved for use in everyone 18 years and older."

 

This year, there are two strain changes, the company noted. The new vaccine formulation will be available to distributors and retailers in mid-August.  

 

A recent clinical study of the quadrivalent version of Flublok in approximately 9,000 adults 50 years and older showed that Flublok recipients were 31% less likely to develop laboratory confirmed influenza than the people that received a traditional egg-based quadrivalent vaccine, the company noted.